Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Don’t blame Big Pharma for insulin’s problems

Rushi Nagalla
Policy
December 4, 2022
Share
Tweet
Share

For diabetics, insulin matters as much as H2O. Unfortunately, insulin’s a hell of a lot more expensive than bottled water. High insulin prices force approximately nine million Americans to balance their wallet and well-being.

The American Action Forum reported that a type-one diabetic’s average yearly expense for insulin was $~6000 (i.e., $500/month). It’s easy to lambast Big Pharma companies for the current state of insulin’s affairs, but history and market behavior gives a bit of critical nuance. Diabetes used to be a death sentence, with only diet changes being the main tools to fight the disease over a hundred years ago. However, nutrition is a blunt instrument to blood sugar, as interest rates are to inflation and the economy. Not to mention that several patients find it difficult to adopt major lifestyle changes. In 1922, a team of doctors and biochemists produced the earliest version of lab-drawn insulin alongside Eli Lilly and the University of Toronto.

Now, that drug’s genetically modified and versatile for several diabetic issues. Today we have three major pharma companies (Eli Lilly, Novo Nordisk, and Sanofi) manufacturing various forms of what might be considered a scientific miracle. That oligopoly is part of why insulin commands a massive price. But there’s more to the insulin market than Big Pharma alone.

Insulin keeps getting expensive partly because more people are getting diagnosed with diabetes every year — which pushes up overall demand. The other factors behind rising prices stem from that market’s several players: manufacturers, wholesalers, pharmacies, pharmacy benefit managers (PBMs), health plans, and, of course, patients. Manufacturers give the drug to wholesalers, usually at a bulk discount, while paying out rebates to PBMs for higher formulary placement.

Wholesalers are the majority of insulin makers’ revenues due to pressure from PBMs. Pharmacies pay wholesalers for the product and bill health plans for reimbursement. Patients then get their insulin from the pharmacy with insurance, cash, or drug assistance programs.

Health plans cover the meds (or not) and reimburse PBMs for services. PBMs take rebates from manufacturers to, in principle, bring the overall insulin cost down. In practice, that step isn’t so clear. With the number of entities involved and the secrecy of coverage negotiations, the actual sticker price listed by insulin makers isn’t what patients pay. That being said, the list price is still a proxy for price behavior up and down most of the insulin supply chain.

Between 2014 and 2018, the average list price per 100 units of insulin rose, yet the net price (where manufacturers draw their sales from) fell. The real story is how the net cost to the insulin health care system stayed flat. Manufacturers are taking discounts, yet both health plans and pharmacy benefit managers aren’t passing those savings along to patients. Such behavior is why the middlemen’s share of insulin expenses went from 30 percent in 2014 to 53 percent by 2018. The middlemen supposedly negotiating prices down maintain their profits by keeping the savings, while drug makers want to keep their margins as well. List prices rise to compensate. The cycle continues.

Lawmakers have started to act on this phenomenon. Both states and the feds have been applying copay caps, meaning that a patient’s monthly expense for insulin would have a ceiling regardless of a health plan’s deductible. As part of the Inflation Reduction Act, Congress passed a bill limiting monthly insulin copays to $35 a month for Medicare patients. Colorado broke ground with an insulin cap in January 2020. 13 states enacted their own rules by June 2021. State-based caps mostly target patients with commercial insurance. Yet those most in need of cheaper insulin are Medicaid and uninsured patients. Neither are beneficiaries of most copay cap laws. The state-level caps do not apply to all commercial insurance plans to begin with. It’s mostly single-state health plans that have to abide by cost limits. Patients who get insurance through an employer with multi-state coverage may not qualify for insulin assistance.

While it’s a little early to gauge the price caps’ impact, such rules potentially set a precedent for less diabetes research in the future. Insulin manufacturers would likely need to accept more rebate concessions while raising list prices to compensate for potential margin declines. Eventually, the usage of insulin for the average consumer becomes untenable.

The diabetics of tomorrow, and there will be plenty, would suffer. Patients signing up for insurance now should request summaries of benefits and coverage documents as well as published insurer formularies to seek the best possible insulin coverage. Contacting a local plan broker and insurance marketplace is a more reasonable first step than waiting for lawmakers to concoct smarter insulin coverage.

Rushi Nagalla is co-founder of a dermatology practice.

Image credit: Shutterstock.com

Prev

Bulletproof backpacks: There’s more we can do [PODCAST]

December 3, 2022 Kevin 0
…
Next

7 things I’ve learned after 12 years of private relationship-based direct care in Canada

December 4, 2022 Kevin 0
…

ADVERTISEMENT

Tagged as: Diabetes, Endocrinology

Post navigation

< Previous Post
Bulletproof backpacks: There’s more we can do [PODCAST]
Next Post >
7 things I’ve learned after 12 years of private relationship-based direct care in Canada

ADVERTISEMENT

More by Rushi Nagalla

  • Is your smartwatch smart about your health?

    Rushi Nagalla
  • Make your health insurance broker a translator, not a shopper

    Rushi Nagalla
  • America trains enough doctors: Redefining medical supply and demand

    Rushi Nagalla

Related Posts

  • Why you shouldn’t be happy with $137 insulin

    Elisabeth Rosenthal, MD
  • a desk with keyboard and ipad with the kevinmd logo

    MKSAP: 45-year-old woman with type 2 diabetes mellitus

    mksap
  • The people vs. opioid pharma: Pharma wins again

    Rebecca Thaxton, MD
  • Type 1 diabetes is no fun

    Ryan Ritchie
  • Questions about pharma pricing and marketing

    Martha Rosenberg
  • A medical educator’s poignant epiphany

    Robert Marion, MD

More in Policy

  • The One Big Beautiful Bill and the fragile heart of rural health care

    Holland Haynie, MD
  • Why health care leaders fail at execution—and how to fix it

    Dave Cummings, RN
  • Healing the doctor-patient relationship by attacking administrative inefficiencies

    Allen Fredrickson
  • The hidden health risks in the One Big Beautiful Bill Act

    Trevor Lyford, MPH
  • The CDC’s restructuring: Where is the voice of health care in the room?

    Tarek Khrisat, MD
  • Choosing between care and country: a dual citizen’s Independence Day reflection

    Kathleen Muldoon, PhD
  • Most Popular

  • Past Week

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why timing, not surgery, determines patient survival

      Michael Karch, MD | Conditions
    • Why health care leaders fail at execution—and how to fix it

      Dave Cummings, RN | Policy
    • How digital tools are reshaping the doctor-patient relationship

      Vineet Vishwanath | Tech
  • Past 6 Months

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
  • Recent Posts

    • Why point-of-care ultrasound belongs in every emergency department triage [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why PSA levels alone shouldn’t define your prostate cancer risk

      Martina Ambardjieva, MD, PhD | Conditions
    • How to handle chronically late patients in your medical practice

      Neil Baum, MD | Physician
    • Reframing chronic pain and dignity: What a pain clinic teaches us about MAiD and chronic suffering

      Olumuyiwa Bamgbade, MD | Conditions
    • How early meetings and after-hours events penalize physician-mothers

      Samira Jeimy, MD, PhD and Menaka Pai, MD | Physician
    • Why medicine must evolve to support modern physicians

      Ryan Nadelson, MD | Physician

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

Leave a Comment

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why timing, not surgery, determines patient survival

      Michael Karch, MD | Conditions
    • Why health care leaders fail at execution—and how to fix it

      Dave Cummings, RN | Policy
    • How digital tools are reshaping the doctor-patient relationship

      Vineet Vishwanath | Tech
  • Past 6 Months

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
  • Recent Posts

    • Why point-of-care ultrasound belongs in every emergency department triage [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why PSA levels alone shouldn’t define your prostate cancer risk

      Martina Ambardjieva, MD, PhD | Conditions
    • How to handle chronically late patients in your medical practice

      Neil Baum, MD | Physician
    • Reframing chronic pain and dignity: What a pain clinic teaches us about MAiD and chronic suffering

      Olumuyiwa Bamgbade, MD | Conditions
    • How early meetings and after-hours events penalize physician-mothers

      Samira Jeimy, MD, PhD and Menaka Pai, MD | Physician
    • Why medicine must evolve to support modern physicians

      Ryan Nadelson, MD | Physician

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Leave a Comment

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...